Search

Your search keyword '"D Joshi"' showing total 45 results

Search Constraints

Start Over You searched for: Author "D Joshi" Remove constraint Author: "D Joshi" Journal alzheimer's & dementia Remove constraint Journal: alzheimer's & dementia
45 results on '"D Joshi"'

Search Results

1. Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale

2. [P2–383]: COMPARISON OF REGIONAL FLORTAUCIPIR PET TO QUANTITATIVE TAU AND AMYLOID IMMUNOASSAY IN PATIENTS WITH ALZHEIMER's DISEASE PATHOLOGY: A PILOT CLINICO‐PATHOLOGICAL STUDY

3. [O5–01–01]: PET BIOMARKERS IN THE EXPEDITION 3 TRIAL OF PATIENTS WITH MILD AD

4. [P4–530]: MODELING OF TAU TRAJECTORIES ACROSS THE ALZHEIMER's DISEASE SPECTRUM USING [18F]‐FLORTAUCIPIR PET IMAGING

5. [IC‐01–04]: A ROBUST, SIMPLIFIED BRAAK‐TYPE CLASSIFICATION SCHEME FOR FLORTAUCIPIR F‐18 TAU PET IMAGES

7. [IC‐P‐081]: THE ASSOCIATION OF TAU BURDEN IN CEREBRAL LOBES AND FUNCTIONAL BRAIN NETWORKS WITH PERFORMANCE IN DIFFERENT COGNITIVE DOMAINS

9. [P4–227]: THE ASSOCIATION OF TAU BURDEN IN CEREBRAL LOBES AND FUNCTIONAL BRAIN NETWORKS WITH PERFORMANCE IN DIFFERENT COGNITIVE DOMAINS

10. O1‐07‐02: Image Patterns and Clinical Phenotypes Associated with Fastest Increase of TAU Burden Measured by Longitudinal [18F]‐AV‐1451 (T807) PET Studies

11. IC‐P‐194: Image Patterns and Clinical Phenotypes Associated with Fastest Increase of TAU Burden Measured by Longitudinal [18F]‐Av‐1451 (T807) PET Studies

12. O4‐07‐01: Evolution of [ 18 F]Av‐1451 Pet Tau Signal: Interim Analysis of an 18‐Month Phase 2 Study

14. IC‐P‐022: Conversion of Amyloid Quantitation With Florbetapir Suvr to The Centiloid Scale

15. P3‐351: Dementia Patient's Quality of Life in a Developing Country: Comparison of Three Approaches

16. O4‐02‐05: The Relationship of [18F]Av‐1451 Pet Tau Images to Changes in Cognition Over Time

17. Amyloid imaging and cognitive decline in nondemented oldest‐old: The 90+ Study

19. O3‐01‐04: Comparison of reference regions for improved detection of change in florbetapir PET from phase 3 solanezumab trials

20. IC‐P‐165: Understanding the topology of 18 F‐AV‐1451 (also known as T807) PET tau images in Alzheimer's disease

21. O1‐07‐06: Hippocampal sparing and limbic predominant tau subtypes of Alzheimer's disease determined in vivo using [18F]‐AV‐1451 PET imaging

22. P4‐259: Relationships between cognitive assessments and spatial distribution of neuropathological tau as assessed by 18 F AV‐1451 PET scanning

24. IC‐P‐030: Comparison of reference regions for improved detection of change in florbetapir PET from phase 3 solanezumab trials

26. IC‐P‐183: EMPLOYING EARLY UPTAKE DATA FROM F18‐FLORBETAPIR SCANS AS AN ESTIMATE OF REGIONAL CEREBRAL BLOOD FLOW: COMPARISON TO F18‐FDG

27. P4‐316: MEASURING CHANGE IN BETA‐AMYLOID BURDEN OVER TIME USING FLORBETAPIR‐PET AND A SUBCORTICAL WHITE MATTER REFERENCE REGION

28. P4‐311: IS FLORBETAPIR‐PET OCCIPITAL SUVR A LATE BIOMARKER IN MILD OR MODERATE AD DEMENTIA AS COMPARED TO HIPPOCAMPAL VOLUME?

29. P4‐136: DOES HIPPOCAMPAL VOLUME PREDICT POSITIVE AMYLOID STATUS ON FLORBETAPIR‐PET IN HEALTHY CONTROLS AND PRODROMAL STAGES OF ALZHEIMER'S DISEASE?

30. P4‐314: TEST‐RETEST DATA FOR THE TAU PET IMAGING AGENT 18F‐AV‐1451 (PREVIOUSLY, 18F‐T807)

31. DT‐02–01: First case report: Image to autopsy correlation for tau imaging with [18F]‐T808 (AV‐680)

32. P4–417: Incidence and clinical progression of placebo‐treated amyloid‐negative subjects with mild‐to‐moderate Alzheimer's disease (AD): Results from the phase III PET substudies of bapineuzumab and solanezumab

33. DT‐01–02: Exploratory analyses of regional human brain distribution of the PET tau tracer F18‐labeled T807 (AV‐1541) in subjects with normal cognitive function or cognitive impairment thought to be due to Alzheimer's disease

34. Florbetapir (F18‐AV‐45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging

35. P4‐282: Prognostic significance of Florbetapir (18F‐Florbetapir) PET imaging for future cognitive performance in recently diagnosed MCI: Final results from a 3‐year multicenter longitudinal trial

36. O1‐04‐03: Comparison of florbetapir‐PET scans to postmortem beta‐amyloid histopathology in 59 autopsy cases

37. O4‐07‐03: Florbetapir PET correlates with cognitive decline, PIB PET and CSF markers in the ADNI database

38. P2‐105: PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F‐AV‐133 together distinguish Alzheimer's disease from DLB patients

39. P2‐058: Quality of life in Alzheimer's and dementia patients in a developing country: Comparison of three approaches

41. P1‐084: PET imaging of β‐amyloid with florpiramine F18 (18F‐AV‐45): Preliminary results from a phase II study of cognitively normal elderly subjects, individuals with mild cognitive impairment, and patients with a clinical diagnosis of Alzheimer's disease

42. O1‐01‐03: Relationship between regional amyloid levels and cognitive performance in healthy controls, MCI subjects, and patients with alzheimer's: Phase II results from a florpiramine F18 PET imaging study

44. P2‐025: A semiautomated method for quantification of 18F‐labelled amyloid plaque imaging agents based on volume of interest and voxel‐based statistical analyses

45. P2‐005: PET imaging of amyloid‐beta in Alzheimer's disease with 18 F‐av‐144

Catalog

Books, media, physical & digital resources